Stabilis

Digoxin



Noms commerciaux

Cardixin	Egypte
Celoxin	Inde
Digibind	Australie, Etats Unis d'Amérique, Finlande, Grande Bretagne, Nouvelle Zélande
Digocard	Argentine
Digosin	Japon
Digossina	Italie
Digoxin	Argentine, Canada, Etats Unis d'Amérique, Finlande, Grande Bretagne, Hongrie, Iran, Pologne, Suède
Digoxina	Argentine, Chili, Equateur, Espagne, Pérou, Vénézuela
Digoxine	France, Grèce, Roumanie, Suisse, Turquie
Dixin	Inde
Geoxin	Inde
Gonet	Mexique
Lanacrist	Suède
Lanibos	Arabie Saoudite
Lanicor	Allemagne
Lanoxin	Arabie Saoudite, Australie, Belgique, Chili, Egypte, Emirats Arabes Unis, Etats Unis d'Amérique, Grande Bretagne, Iran, Irlande, Italie, Luxembourg, Malaisie, Mexique, Norvège, Nouvelle Zélande, Pays bas, Portugal
Loxinan	Mexique

Stabilité des solutions

		2,5 µg/ml	23-26°C		48			618
		2,5 µg/ml	4°C		48			618
		50 µg/ml	23-27°C		180			4690
		50 µg/ml	3-7°C		180			4690

	RL	2,5 µg/ml	23°C-26°C		6			618

Stabilité en mélange

		125 µg/ml	22°C-23°C		Milrinone lactate : 0,1 mg/ml	4	191
		50 µg/ml	22°C-23°C		Milrinone lactate : 0,35 mg/ml	4	191

Facteur influençant la stabilité

					1269

Compatibilités

		Digoxin : 250 µg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Digoxin : 250 µg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Digoxin : 250 µg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Digoxin : 250 µg/ml Anidulafungin : 0.5 mg/ml		1982
		Digoxin : 250 µg/ml Bivalirudin : 5 mg/ml		1713
		Digoxin : 2 µg/ml Bretylium tosilate : 1 mg/ml		1193
		Digoxin : 250 µg/ml Caffeine : 10 mg/ml		3964
		Digoxin : 250 µg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Digoxin : 250 µg/ml Cefmetazole sodium : 100 mg/ml		93
		Digoxin : 250 µg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Digoxin : 250 µg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Digoxin : 250 µg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Digoxin : 250 µg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Digoxin : 250 µg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828

	✓	Digoxin : 2.5 µg/ml Cimetidine hydrochloride : 3 mg/ml	◆	1201
	✓	Digoxin : 250 µg/ml Ciprofloxacin lactate : 2 mg/ml	▲	289
	✓	Digoxin : 250 µg/ml Ciprofloxacin lactate : 2 mg/ml	▲◆	288
	✓	Digoxin : 250 µg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml	◆	299
	✓	Digoxin : 50 µg/ml Cloxacillin sodium : 100 mg/ml	💧	3012
	✓	Digoxin : 250 µg/ml Dexmedetomidine : 4 µg/ml	▲	1712
	✓	Digoxin : 500 µg/ml Diltiazem hydrochloride : 1 & 5 mg/ml	▲	198
	✓	Digoxin Dimenhydrinate		2087
24	✗	Digoxin : 4 µg/ml Dobutamine hydrochloride : 1 mg/ml	▲◆	1058
	✓	Digoxin : 250 µg/ml Doripenem : 5 mg/ml	▲◆	2262
	✓	Digoxin : 250 µg/ml Famotidine	◆	397
	✓	Digoxin : 250 µg/ml Fenoldopam mesylate : 80 µg/ml	▲	1803
	✓	Digoxin : 100 µg/ml Fentanyl citrate : 50 µg/ml	◆	63
	✓	Digoxin : 25 µg/ml Flucloxacillin sodium : 20 mg/ml	▲	1232
○	✗	Digoxin : 250 µg/ml Fluconazole : 2 mg/ml	▲	496
○	✗	Digoxin : 250 µg/ml Foscarnet sodium : 24 mg/ml	∅	73
	✓	Digoxin : 250 µg/ml Fosfomycin : 30 mg/ml	▲◆	4055
	✓	Digoxin : 25 µg/ml Furosemide : 1 mg/ml	▲	1232
	✓	Digoxin : 250 µg/ml Hetastarch : 60 mg/ml	💧®	1721
	✓	Digoxin : 50 µg/ml Ketamine hydrochloride : 50 mg/ml		2109
	✓	Digoxin : 250 µg/ml Levosimendan : 0,025 & 0,05 mg/ml		4571
	✓	Digoxin : 1 µg/ml Lidocaine hydrochloride : 2 mg/ml	RL	619
	✓	Digoxin : 250 µg/ml Meropenem : 50 mg/ml	💧	4319
	✓	Digoxin : 50 & 125 µg/ml Milrinone lactate : 0.1 & 0.35 mg/ml	◆	191
	✓	Digoxin : 250 µg/ml Morphine sulfate : 1 mg/ml	◆	62
	✓	Digoxin : 50 µg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408

		Digoxin Pantoprazole sodium		2090
		Digoxin : 250 µg/ml Pethidine hydrochloride : 10 mg/ml		62
		Digoxin : 250 µg/ml Potassium chloride : 40 mEq/l	RL	730
		Digoxin : 250 µg/ml		301
		Digoxin : 0,25 µg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Digoxin : 250 µg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Digoxin : 250 µg/ml Lansoprazole : 0.55 mg/ml		1625
		Digoxin : 1 µg/ml Lidocaine hydrochloride : 2 mg/ml		619
		Digoxin : 250 µg/ml Linezolid : 2 mg/ml	∅	1925
		Digoxin : 250 µg/ml Meropenem : 1 & 50 mg/ml		266
		Digoxin : 100 µg/ml Midazolam hydrochloride : 1 mg/ml		176
		Digoxin : 50 µg/ml N-acetylcysteine : 200 mg/ml	∅	3766
		Digoxin : 250 µg/ml Plazomicin sulfate : 24 mg/ml		4145
		Digoxin : 250 µg/ml Potassium chloride : 40 mEq/l		730
		Digoxin : 250 µg/ml Propofol : 10 mg/ml	∅	300
		Digoxin : 250 µg/ml Propofol		660
		Digoxin : 250 µg/ml		1415
		Digoxin : 0.4 µg/ml		1338
		Digoxin : 50 µg/ml	RL	4603
		Digoxin : 250 µg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Digoxin : 250 µg/ml Tacrolimus : 1000 µg/ml		479
		Digoxin : 250 µg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Digoxin : 250 µg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Digoxin : 250 µg/ml Telavancin hydrochloride : 7,5 mg/ml		3254
		Digoxin : 2 µg/ml Verapamil hydrochloride : 0,08 mg/ml		706

Voie d'administration

Bibliographie

	Type	Source
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
63	Revue	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
191	Revue	Riley CM. Stability of milrinone and digoxin, furosemide, procainamide hydrochloride, propranolol hydrochloride, quinidine gluconate, or verapamil hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1988 ; 45: 2079-2091.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
289	Revue	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.

301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
618	Revue	Shank WA, Coupal JJ. Stability of digoxin in common large-volume injections. Am J Hosp Pharm 1982 ; 39: 844-846.
619	Revue	Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. Am J Hosp Pharm 1982 ; 39: 1013-1015.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
706	Revue	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.
730	Revue	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1058	Revue	Kirschenbaum HL, Aronoff W, Piltz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1193	Revue	Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. Am J Hosp Pharm 1983 ; 40: 1010-1012.
1201	Revue	Yuhas EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1269	Revue	DeMuynck C, De Vroe C, Remon JP, Colardyn F. Binding of drugs to end-line filters: a study of four commonly administered drugs in intensive care units. J Clin Pharm Ther 1988 ; 13: 335-340.
1338	Revue	Baptista RJ, Dumas GJ, Bistrian BR, Condella F, Blackburn GL. Compatibility of total nutrient admixtures and secondary cardiovascular medications. Am J Hosp Pharm 1985 ; 42: 777-778.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.

1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.

3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4571	Laboratoire	Levosimendan (Simdax 2.5 mg/ml) - Summary of Product Characteristics Orion Pharma 2010
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4690	Revue	Friciu M, Marcelin R.B, Bédard P, Forest J.M, Leclair G. Stability of Compounded Digoxin Solution 0.05mg/mL for Injection. Hosp Pharm 2022 ; 57, 2: 294-299.

Dictionnaire

	Cardiotonique		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	NaCl 0,9% ou glucose 5%		Lumière
	Heure		A l'abri de la lumière
	Chlorure de sodium 0,9%		Jour
RL	Ringer lactate		Stabilité en mélange
	Solvant		Molécule
	Glucose 5%		Facteur influençant la stabilité
	Filtration		Provoque
	Adsorption		Compatibilités
	Précipitation immédiate		Incompatible
	Compatible	∅	Aucun
	Eau pour préparation injectable		Changement de couleur en 24 heures
	Dégagement gazeux		Solvant spécifique
	Précipitation en 4 heures		Nutrition parentérale (mélange binaire)
	Instabilité de l'émulsion en 1 heure		Nutrition parentérale (mélange ternaire)
	Turbidité immédiate		Voie d'administration
	Perfusion intraveineuse		Intramusculaire
	Bibliographie		Dictionnaire